Avacta Group plc (GB:AVCT) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avacta Group plc is set to present new preclinical data on their revolutionary pre|CISION™ cancer treatment platforms at the 2024 EORTC-NCI-AACR Symposium. The company’s advancements include AVA6103, a potent peptide drug conjugate designed for tumor-specific delivery, and a new class of Affirmer® Drug Conjugates aiming for higher specificity and reduced systemic exposure. These innovations highlight Avacta’s commitment to developing highly targeted cancer therapies with the potential to improve patient outcomes.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.